Frazier Life Sciences Management L.P. Makes New Investment in Ascendis Pharma A/S (NASDAQ:ASND)

Frazier Life Sciences Management L.P. bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 133,333 shares of the biotechnology company's stock, valued at approximately $19,908,000. Ascendis Pharma A/S makes up about 0.8% of Frazier Life Sciences Management L.P.'s portfolio, making the stock its 28th biggest position. Frazier Life Sciences Management L.P. owned approximately 0.22% of Ascendis Pharma A/S at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Public Employees Retirement System of Ohio bought a new position in shares of Ascendis Pharma A/S in the third quarter valued at $1,101,000. Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S in the third quarter valued at $60,000. Nomura Asset Management Co. Ltd. lifted its stake in shares of Ascendis Pharma A/S by 42.5% in the third quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company's stock valued at $2,688,000 after buying an additional 5,371 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Ascendis Pharma A/S in the third quarter valued at about $886,000. Finally, Main Management ETF Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S in the third quarter valued at about $927,000.

Analyst Ratings Changes

A number of research firms recently issued reports on ASND. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a report on Tuesday, September 17th. Jefferies Financial Group lifted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a research report on Tuesday, August 13th. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. Bank of America lifted their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. Finally, Wedbush reiterated an "outperform" rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $191.77.

Ascendis Pharma A/S Trading Down 2.1 %

Ascendis Pharma A/S stock traded down $2.75 during midday trading on Tuesday, hitting $129.67. The stock had a trading volume of 306,478 shares, compared to its average volume of 449,891. The firm's fifty day moving average is $129.86 and its two-hundred day moving average is $132.69. The company has a market capitalization of $7.86 billion, a PE ratio of -16.05 and a beta of 0.67. Ascendis Pharma A/S has a 52-week low of $101.43 and a 52-week high of $161.00.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.